GeneDx Holdings (WGS) executive compensation, 2026 proxy

Katherine Stueland, Chief Executive Officer, was paid $13.5M in fiscal year 2025, up 206% from $4.4M the year before.

Filed
April 30, 2026
Annual meeting
June 18, 2026
Pay year
fiscal year 2025
Named executives
3
CEO total pay
$13.5M+206% vs prior year
CEO pay in equity
87%$11.7M in awards
2025 Revenue
$427.5M41% increase year-over-year
Adjusted Gross Margin
71%Up from 65% in 2024
Adjusted Net Income
$41.8MCompared to $9.4M in 2024
Annual Incentive Payout
150%Percentage of target

How Stueland was paid

$13.5M in total for fiscal year 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary5%Stock awards87%Non-equity incentive8%All other compensation0%

Named executive officers

ExecutiveTotal
Katherine StuelandChief Executive Officer$13,547,219
Kevin FeeleyChief Financial Officer$4,688,926
Bryan DechairoChief Operating Officer$3,582,375

What changed and why

  • $13.5MChief Executive Officer total compensation increased to $13,547,219 in fiscal year 2025 from $4,421,800 in 2024.
  • $427.5MRevenues grew by 41% year-over-year to reach $427.5 million in fiscal year 2025.
  • 71%Adjusted gross margin expanded to 71% for full year 2025 compared to 65% in 2024.
  • 150%Annual incentive awards were approved and paid at 150% of target based on strong performance.
  • 50%Long-term equity incentives consisted of a mix of 50% performance-based restricted stock units and 50% service-based restricted stock units.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.